DE69034070D1 - Racemisches Huperzin A - Google Patents

Racemisches Huperzin A

Info

Publication number
DE69034070D1
DE69034070D1 DE69034070T DE69034070T DE69034070D1 DE 69034070 D1 DE69034070 D1 DE 69034070D1 DE 69034070 T DE69034070 T DE 69034070T DE 69034070 T DE69034070 T DE 69034070T DE 69034070 D1 DE69034070 D1 DE 69034070D1
Authority
DE
Germany
Prior art keywords
huperzine
racemic
racemic huperzine
medicament
cholesterase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69034070T
Other languages
English (en)
Other versions
DE69034070T2 (de
Inventor
Alain P Kozikowski
Yan Xia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Foundation for Medical Education and Research
Original Assignee
Mayo Foundation for Medical Education and Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation for Medical Education and Research filed Critical Mayo Foundation for Medical Education and Research
Publication of DE69034070D1 publication Critical patent/DE69034070D1/de
Application granted granted Critical
Publication of DE69034070T2 publication Critical patent/DE69034070T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE69034070T 1989-02-21 1990-02-21 Racemisches Huperzin A Expired - Fee Related DE69034070T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/313,118 US4929731A (en) 1989-02-21 1989-02-21 Method for the synthesis of huperzine A and analogs thereof and compounds useful therein

Publications (2)

Publication Number Publication Date
DE69034070D1 true DE69034070D1 (de) 2003-06-12
DE69034070T2 DE69034070T2 (de) 2003-12-18

Family

ID=23214460

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69033970T Expired - Fee Related DE69033970T2 (de) 1989-02-21 1990-02-21 Huperzin a analoge verbindungen
DE69034226T Expired - Fee Related DE69034226T2 (de) 1989-02-21 1990-02-21 Verfahren zur Synthese von Huperzin A und Analoge desselben sowie von darin verwendbaren Verbindungen
DE69034070T Expired - Fee Related DE69034070T2 (de) 1989-02-21 1990-02-21 Racemisches Huperzin A

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE69033970T Expired - Fee Related DE69033970T2 (de) 1989-02-21 1990-02-21 Huperzin a analoge verbindungen
DE69034226T Expired - Fee Related DE69034226T2 (de) 1989-02-21 1990-02-21 Verfahren zur Synthese von Huperzin A und Analoge desselben sowie von darin verwendbaren Verbindungen

Country Status (10)

Country Link
US (1) US4929731A (de)
EP (3) EP0460062B1 (de)
JP (1) JP2933386B2 (de)
AT (3) ATE219061T1 (de)
CA (2) CA2047744C (de)
DE (3) DE69033970T2 (de)
DK (2) DK1167354T3 (de)
ES (2) ES2194003T3 (de)
HK (1) HK1030604A1 (de)
WO (1) WO1990009993A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177082A (en) * 1985-11-05 1993-01-05 Yu Chao Mei Huperzines and analogs
US5104880A (en) * 1991-05-01 1992-04-14 Mayo Foundation For Medical Education And Research Huperzine a analogs as acetylcholinesterase inhibitors
US5145973A (en) * 1991-09-30 1992-09-08 Union Carbide Chemicals & Plastics Technology Corporation Oxa-Bicyclic polyfunctional compounds and preparation thereof
US5206393A (en) * 1991-09-30 1993-04-27 Union Carbide Chemicals & Plastics Technology Corporation Oxa-bicyclic polyfunctional compounds and preparation thereof
US5547960A (en) * 1994-09-07 1996-08-20 Mayo Foundation For Medical Education And Research C-10 analogs of huperzine a
CN1125725A (zh) * 1994-12-28 1996-07-03 中国科学院上海药物研究所 一类海克林碱衍生物及它的用途
USRE38460E1 (en) 1994-12-28 2004-03-09 Shanghai Institute Of Materia Medica Chinese Academy Of Sciences Huperzine A derivatives, their preparation and their use
US6524616B1 (en) * 1999-06-25 2003-02-25 Wake Forest University Health Services Compositions and methods for treating or preventing neurodegeneration and cognitive decline and dysfunction associated with alzheimer's disease, aging, other dementia related disorders and estrogen deficiency related conditions
US6271379B1 (en) * 2000-03-08 2001-08-07 Georgetown University Intermediates useful for the synthesis of huperzine A
US6436972B1 (en) 2000-04-10 2002-08-20 Dalhousie University Pyridones and their use as modulators of serine hydrolase enzymes
US6369052B1 (en) 2000-08-07 2002-04-09 Georgetown University Combination of huperzine and nicotinic compounds as a neuroprotective agent
KR100390777B1 (ko) * 2000-12-19 2003-07-10 한국화학연구원 피리돈 유도체의 제조방법
US6967206B2 (en) 2002-12-05 2005-11-22 Access Business Group International Llc Compositions and methods for increasing growth hormone levels
EP3056200B1 (de) * 2005-05-23 2023-09-06 President and Fellows of Harvard College Huperzin zur verwendung in der behandlung von einem anfall
US8097726B2 (en) * 2006-05-17 2012-01-17 Industrial Technology Research Institute Huperzine a compound for treatment of alzheimer's disease
US20090247754A1 (en) * 2008-03-25 2009-10-01 Debiopharm S.A. Method of preparing huperzine a and derivatives thereof
CA2736114A1 (en) * 2008-09-04 2010-03-11 President And Fellows Of Harvard College Treatment of neurological disorders using huperzine
CN104496900A (zh) * 2014-12-15 2015-04-08 陕西嘉禾植物化工有限责任公司 一种2-甲氧基-6-酮-5,7,8-三氢-喹啉的制备方法
CN104496998B (zh) * 2014-12-15 2017-07-11 陕西嘉禾生物科技股份有限公司 一种1′‑苄基‑2′‑酮‑5′，7′，8′‑三氢‑螺‑[1，3‑二氧五环‑2]‑喹啉的制备方法
CN109705038B (zh) * 2017-10-25 2020-11-03 广州市朗启医药科技有限责任公司 石杉碱甲的合成方法
CN114716449B (zh) * 2022-04-12 2023-09-29 浙江工业大学 一种2-甲氧基-6-乙二醇缩酮-5,7,8-三氢喹啉的制备方法

Also Published As

Publication number Publication date
WO1990009993A2 (en) 1990-09-07
ATE239709T1 (de) 2003-05-15
EP1026157A3 (de) 2004-08-11
EP1167354A3 (de) 2002-01-09
DE69033970T2 (de) 2002-10-02
DK1167354T3 (da) 2003-09-01
EP0460062A1 (de) 1991-12-11
ES2194003T3 (es) 2003-11-16
ATE330943T1 (de) 2006-07-15
DE69034226T2 (de) 2007-06-21
CA2047744C (en) 2000-05-02
DK0460062T3 (da) 2002-08-26
WO1990009993A3 (en) 1990-11-01
EP1167354B1 (de) 2003-05-07
JP2933386B2 (ja) 1999-08-09
DE69034226D1 (de) 2006-08-03
CA2047744A1 (en) 1990-08-22
EP1026157A2 (de) 2000-08-09
ES2173858T3 (es) 2002-11-01
EP0460062B1 (de) 2002-06-12
CA2296915A1 (en) 1990-08-22
DE69033970D1 (de) 2002-07-18
DE69034070T2 (de) 2003-12-18
ATE219061T1 (de) 2002-06-15
US4929731A (en) 1990-05-29
HK1030604A1 (en) 2001-05-11
EP1167354A2 (de) 2002-01-02
EP0460062A4 (en) 1992-07-01
EP1026157B1 (de) 2006-06-21

Similar Documents

Publication Publication Date Title
ATE239709T1 (de) Racemisches huperzin a
SE9504661D0 (sv) New compounds
UA26303A1 (uk) Фармацевтичhа композиція, яка має імуhосупресорhу та аhтимікробhу активhість
ES2140565T3 (es) Nuevos derivados de pirazina-carboxamida, su preparacion y su utilizacion en medicamentos.
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
DE69011353D1 (de) Oral anzuwendende antifungale Arzneizubereitungen.
BR9811099A (pt) Inibidores de urocinase
IT8323205A0 (it) Composizioni farmaceutiche adattivita' antiinfiammatoria e/o analgesica, non ulcerogene.
ATE214610T1 (de) Neuartige pharmazeutische verwendungen von krill- enzymen
HUP9602498A2 (hu) Antimikrobiális hatású gyógyászati készítmények
HUP0004282A2 (hu) 2-Halogén-6-0-szubsztituált ketolidszármazékok
AU563831B2 (en) N-(2-amino-3,5-dibromobenzyl)- trans-4-amino-cyclohexanol derivatives
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
NO911459D0 (no) Anvendelse av metallion-komplekser som belegginhibitorer.
ES2089286T3 (es) Nuevas 2-amino-5-ciano-1,4-dihidropiridinas, procedimiento para su preparacion y su uso en medicamentos.
SE9504662D0 (sv) New compounds
EA200000531A1 (ru) Применение кетолидов для профилактики тромботических артериальных осложнений, связанных с атеросклерозом
LV10917A (lv) Bambuterina pielietojums lipidu saturu pazeminosu farmaceitisku kompoziciju pagatavosanai
ATE102934T1 (de) Fluorierte flavon-essigsaeure.
YU2394A (sh) Lizin so 6-hloro-5-fluoro-3-(-2-tenoil)-2-oksindol-1-karboksamida
IT9048244A0 (it) Composizione farmaceutica ad effetto cicatrizzante.
KR960021044A (ko) 세코노가노사이드를 포함하는 b형 간염 치료제
FI935385A0 (fi) Alfa-amiderande enzympompositioner och foerfaranden foer deras framstaellning och anvaendning
PT99238A (pt) Processo para a preparacao de composicoes farmaceuticas contendo um inibidor da enzima conversora da angiotensina e um inibidor da actividade do tromboxano a2, utilizadas no tratamento de nefropatias
IT8321358A0 (it) Derivati ad attivita' terapeutica della s-carbossimetilcisteina, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee